Trial Profile
Phase II Study to Compare Fulvestrant (F) 500mg Plus Placebo vs F 500mg Plus Palbociclib as First Line Treatment for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer Sensitive to Endocrine Therapy. GEICAM/2014-12
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms FLIPPER
- 10 Dec 2021 Results published in the European Journal of Cancer
- 21 Sep 2020 Primary endpoint (Efficacy in terms of the rate of Progression-Free Survival (PFS)) has been met.
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress